Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Clinical trial NCT05333809 · UNKNOWN

Trial details

NCT number: NCT05333809
Sponsor: Shanghai Zhongshan Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Neoplasms

Start date: 2022-07-01
Primary completion: 2024-07-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.